Diatide signs license deal with Angstrom

Radiopharmaceutical firm Diatide last month signed a license agreement with Angstrom Pharmaceuticals that will allow Angstrom to develop cancer-fighting pharmaceuticals. Londonderry, NH-based Diatide will have global exclusive rights to imaging and therapeutic agents produced from Angstrom’s tumor-targeting technology. Diatide will pay San Diego-based Angstrom an initial payment, future research and milestone payments, and royalties on product sales, and will provide research support.

Angstrom has developed and patented small cyclic peptides that bind to a key receptor found on the surface of almost all solid tumors, including breast, prostate, colon, and lung. The two firms believe that targeting these receptors with radiotherapeutic agents could obstruct tumor growth.